Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting
Purpose: This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients. Materials and Methods: We retrospectively reviewed the medical records of 199 chemotherapy-na...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Urological Association
2020-01-01
|
| Series: | Investigative and Clinical Urology |
| Subjects: | |
| Online Access: | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-19.pdf |
| _version_ | 1818854548906704896 |
|---|---|
| author | Seung Il Jung Myung Soo Kim Chang Wook Jeong Cheol Kwak Sung Kyu Hong Seok Ho Kang Jae Young Joung Seung Hwan Lee Seok Joong Yun Tae-Hwan Kim Sung Woo Park Seong Soo Jeon Minyong Kang Ji Youl Lee Byung Ha Chung Jun Hyuk Hong Hanjong Ahn Choung-Soo Kim Dong Deuk Kwon |
| author_facet | Seung Il Jung Myung Soo Kim Chang Wook Jeong Cheol Kwak Sung Kyu Hong Seok Ho Kang Jae Young Joung Seung Hwan Lee Seok Joong Yun Tae-Hwan Kim Sung Woo Park Seong Soo Jeon Minyong Kang Ji Youl Lee Byung Ha Chung Jun Hyuk Hong Hanjong Ahn Choung-Soo Kim Dong Deuk Kwon |
| author_sort | Seung Il Jung |
| collection | DOAJ |
| description | Purpose: This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients. Materials and Methods: We retrospectively reviewed the medical records of 199 chemotherapy-naïve patients with mCRPC at 13 tertiary centers in Korea between 2014 and 2017. All patients received enzalutamide daily and 89 patients received concurrent androgen deprivation therapy (ADT). Results: The median age of the patients was 74 years. Initial results showed that 81.5% of the patients had Gleason score ≥8 and 33.3% of the patients had European Cooperative Oncology Group Performance Status 0. The overall mortality rate was 12%. The median OS was not archieved and 76.7% of patients were alive at 30 months. Median time until PSA progression was 6 months. The overall survival rate at 2 years was significantly higher (84.6% vs. 71.7%, p=0.015) and the duration of PSA progression-free survival was significantly longer (8.0 vs. 4.6 months, p=0.008) in patients receiving concurrent ADT than in those receiving enzalutamide alone. The incidence of adverse events of grade 3 or higher was 1.7%. Multivariate Cox proportional hazard analysis indicated that ADT administered concurrently with enzalutamide significantly improved the overall survival (hazard ratio, 0.346; 95% confidence interval, 0.125–0.958). Conclusions: Enzalutamide is effective and safe for chemotherapy-naïve patients with mCRPC. Furthermore, the overall survival was significantly higher in patients receiving enzalutamide and concurrent ADT than in patients receiving enzalutamide alone. |
| first_indexed | 2024-12-19T07:54:28Z |
| format | Article |
| id | doaj.art-1565b3b41ff54be8a3250dcac6fe247a |
| institution | Directory Open Access Journal |
| issn | 2466-0493 2466-054X |
| language | English |
| last_indexed | 2024-12-19T07:54:28Z |
| publishDate | 2020-01-01 |
| publisher | Korean Urological Association |
| record_format | Article |
| series | Investigative and Clinical Urology |
| spelling | doaj.art-1565b3b41ff54be8a3250dcac6fe247a2022-12-21T20:30:02ZengKorean Urological AssociationInvestigative and Clinical Urology2466-04932466-054X2020-01-01611192710.4111/icu.2020.61.1.19Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world settingSeung Il Jung0Myung Soo Kim1Chang Wook Jeong2Cheol Kwak3Sung Kyu Hong4Seok Ho Kang5Jae Young Joung6Seung Hwan Lee7Seok Joong Yun8Tae-Hwan Kim9Sung Woo Park10Seong Soo Jeon11Minyong Kang12Ji Youl Lee13Byung Ha Chung14Jun Hyuk Hong15Hanjong Ahn16Choung-Soo Kim17Dong Deuk Kwon18Department of Urology, Chonnam National University Medical School, Gwangju, Korea.Department of Urology, Chonnam National University Medical School, Gwangju, Korea.Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.Department of Urology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.Department of Urology, Korea University College of Medicine, Seoul, Korea.Department of Urology, Center for Prostate Cancer, Korea National Cancer Center, Goyang, Korea.Department of Urology, Severance Hospital, Yonsei University Health System, Seoul, Korea.Department of Urology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.Department of Urology, Kyungpook National University School of Medicine, Daegu, Korea.Department of Urology, Pusan National University Yangsan Hospital, Yangsan, Korea.Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.Department of Urology, The Catholic University of Korea, Seoul St. Mary Hospital's, College of Medicine, The Catholic University of Korea, Seoul, Korea.Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.Department of Urology, Chonnam National University Medical School, Gwangju, Korea.Purpose: This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients. Materials and Methods: We retrospectively reviewed the medical records of 199 chemotherapy-naïve patients with mCRPC at 13 tertiary centers in Korea between 2014 and 2017. All patients received enzalutamide daily and 89 patients received concurrent androgen deprivation therapy (ADT). Results: The median age of the patients was 74 years. Initial results showed that 81.5% of the patients had Gleason score ≥8 and 33.3% of the patients had European Cooperative Oncology Group Performance Status 0. The overall mortality rate was 12%. The median OS was not archieved and 76.7% of patients were alive at 30 months. Median time until PSA progression was 6 months. The overall survival rate at 2 years was significantly higher (84.6% vs. 71.7%, p=0.015) and the duration of PSA progression-free survival was significantly longer (8.0 vs. 4.6 months, p=0.008) in patients receiving concurrent ADT than in those receiving enzalutamide alone. The incidence of adverse events of grade 3 or higher was 1.7%. Multivariate Cox proportional hazard analysis indicated that ADT administered concurrently with enzalutamide significantly improved the overall survival (hazard ratio, 0.346; 95% confidence interval, 0.125–0.958). Conclusions: Enzalutamide is effective and safe for chemotherapy-naïve patients with mCRPC. Furthermore, the overall survival was significantly higher in patients receiving enzalutamide and concurrent ADT than in patients receiving enzalutamide alone.https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-19.pdfandrogen antagonistsneoplasm metastasisprostate neoplasmstreatment outcome |
| spellingShingle | Seung Il Jung Myung Soo Kim Chang Wook Jeong Cheol Kwak Sung Kyu Hong Seok Ho Kang Jae Young Joung Seung Hwan Lee Seok Joong Yun Tae-Hwan Kim Sung Woo Park Seong Soo Jeon Minyong Kang Ji Youl Lee Byung Ha Chung Jun Hyuk Hong Hanjong Ahn Choung-Soo Kim Dong Deuk Kwon Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting Investigative and Clinical Urology androgen antagonists neoplasm metastasis prostate neoplasms treatment outcome |
| title | Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting |
| title_full | Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting |
| title_fullStr | Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting |
| title_full_unstemmed | Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting |
| title_short | Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting |
| title_sort | enzalutamide in chemotherapy naive patients with metastatic castration resistant prostate cancer a retrospective korean multicenter study in a real world setting |
| topic | androgen antagonists neoplasm metastasis prostate neoplasms treatment outcome |
| url | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-19.pdf |
| work_keys_str_mv | AT seungiljung enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT myungsookim enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT changwookjeong enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT cheolkwak enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT sungkyuhong enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT seokhokang enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT jaeyoungjoung enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT seunghwanlee enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT seokjoongyun enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT taehwankim enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT sungwoopark enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT seongsoojeon enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT minyongkang enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT jiyoullee enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT byunghachung enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT junhyukhong enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT hanjongahn enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT choungsookim enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting AT dongdeukkwon enzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceraretrospectivekoreanmulticenterstudyinarealworldsetting |